Post-essential Thrombocythemia Myelofibrosis
📧 Sign up to get email alerts when something new happens for Post-essential Thrombocythemia Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Extended Access of Momelotinib in Adults With Myelofibrosis [Phase 2]
This clinical trial update notes extended-access use of momelotinib in adults with myelofibrosis, including primary myelofibrosis and relate…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms [Phase 1]
An update on a Phase 1 safety and tolerability study of INCB057643 in myelofibrosis and other advanced myeloid neoplasms, with the trial cur…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes fedratinib in Japanese patients with DIPSS-intermediate/high-risk primary myelofibrosis, post-po…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
This update reports on a completed Phase 1/2 study evaluating the safety, pharmacokinetics, pharmacodynamics, and dose expansion of PXS-5505…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis [Phase 2]
A Phase 2 trial comparing NS-018 to best available therapy in myelofibrosis was terminated, and results have been posted on May 23, 2025.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) [Phase 3]
Phase 3 MANIFEST-2 study of pelabresib (CPI-0610) in myelofibrosis has posted results as of Oct 28, 2024; the trial remains active but not r…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors [Phase 2]
A Phase 2 trial of selinexor in patients with myelofibrosis refractory or intolerant to JAK1/2 inhibitors was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) [Phase 3]
A Phase 3 trial (LIMBER-313) evaluating Parsaclisib in combination with Ruxolitinib for myelofibrosis was terminated, with results posted in…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) [Phase 3]
Phase 3 LIMBER-304 trial evaluating parsaclisib with ruxolitinib in myelofibrosis patients with suboptimal response to ruxolitinib was termi…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]
A Phase 3 trial evaluating fedratinib versus best available therapy in high- or intermediate-risk myelofibrosis subtypes after ruxolitinib f…
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) [Phase 1, Phase 2]
Clinical trial update for Bomedemstat (IMG-7289/MK-3543) in myelofibrosis showing completion and posted results for Phase 1/2 study.
-
CLINICAL_TRIALS trial_result · 2023-05-23Clinical Trial Update: Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF [Phase 3]
Phase 3 trial comparing momelotinib to best available therapy in anemic or thrombocytopenic patients with various subtypes of myelofibrosis;…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis [Phase 3]
Phase 3 trial comparing momelotinib to ruxolitinib in myelofibrosis subjects has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment [Phase 2, Phase 3]
Clinical trial updating the efficacy of KRT-232 versus best available therapy for relapsed/refractory myelofibrosis (Phase 2/Phase 3).
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating jaktinib for patients with myelofibrosis intolerant to ruxolitinib has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]
A Phase 3 trial of fedratinib in patients with primary myelofibrosis and myelofibrosis after polycythemia vera or essential thrombocythemia …
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) [Phase 3]
Phase 3 trial comparing momelotinib to danazol in symptomatic and anemic myelofibrosis has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-01Clinical Trial Update: Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib [Phase 2]
Phase 2 dose-finding study of pacritinib in myelofibrosis patients previously treated with ruxolitinib has completed; results posted in 2022…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis [Phase 2]
Phase 2 trial evaluating KRT-232 or TL-895 in JAK inhibitor–treated myelofibrosis patients remains in status unknown.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) [Phase 1]
Phase 1 study of oral ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocyt…
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF [Phase 1, Phase 2]
Phase 1/2 safety and tolerability trial of oral NS-018 in myelofibrosis patients completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: A Phase 2 Study of RO7490677 In Participants With Myelofibrosis [Phase 2]
Phase 2 clinical trial update for RO7490677 in myeloproliferative neoplasms has completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2021-11-18Clinical Trial Update: Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia [Phase 3]
Phase 3 trial comparing pacritinib to best available therapy in myelofibrosis with thrombocytopenia was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-21Clinical Trial Update: PD-1 Inhibition in Advanced Myeloproliferative Neoplasms [Phase 2]
Phase 2 trial assessing PD-1 inhibition in advanced myeloproliferative neoplasms has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 long-term safety and efficacy update for momelotinib in various myelofibrosis subtypes; study completed with results posted in 2021.